These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 31910860)

  • 1. Future treatments for hereditary hemorrhagic telangiectasia.
    Robert F; Desroches-Castan A; Bailly S; Dupuis-Girod S; Feige JJ
    Orphanet J Rare Dis; 2020 Jan; 15(1):4. PubMed ID: 31910860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of Activin Receptor-Like Kinase 1 in Endothelial Cells Suppresses Development of Arteriovenous Malformations in Mouse Models of Hereditary Hemorrhagic Telangiectasia.
    Hwan Kim Y; Vu PN; Choe SW; Jeon CJ; Arthur HM; Vary CPH; Lee YJ; Oh SP
    Circ Res; 2020 Oct; 127(9):1122-1137. PubMed ID: 32762495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells.
    Albiñana V; Bernabeu-Herrero ME; Zarrabeitia R; Bernabéu C; Botella LM
    Thromb Haemost; 2010 Mar; 103(3):525-34. PubMed ID: 20135064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia.
    Zarrabeitia R; Ojeda-Fernandez L; Recio L; Bernabéu C; Parra JA; Albiñana V; Botella LM
    Thromb Haemost; 2016 Jun; 115(6):1167-77. PubMed ID: 26818701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia.
    Ruiz-Llorente L; Gallardo-Vara E; Rossi E; Smadja DM; Botella LM; Bernabeu C
    Expert Opin Ther Targets; 2017 Oct; 21(10):933-947. PubMed ID: 28796572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
    Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
    Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hereditary Haemorrhagic Telangiectasia, an Inherited Vascular Disorder in Need of Improved Evidence-Based Pharmaceutical Interventions.
    Snodgrass RO; Chico TJA; Arthur HM
    Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33513792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiopoietin-2 Inhibition Rescues Arteriovenous Malformation in a Smad4 Hereditary Hemorrhagic Telangiectasia Mouse Model.
    Crist AM; Zhou X; Garai J; Lee AR; Thoele J; Ullmer C; Klein C; Zabaleta J; Meadows SM
    Circulation; 2019 Apr; 139(17):2049-2063. PubMed ID: 30744395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.
    Tillet E; Bailly S
    Front Genet; 2014; 5():456. PubMed ID: 25620979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment.
    Ardelean DS; Jerkic M; Yin M; Peter M; Ngan B; Kerbel RS; Foster FS; Letarte M
    Angiogenesis; 2014 Jan; 17(1):129-46. PubMed ID: 24061911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital.
    Karlsson T; Cherif H
    Ups J Med Sci; 2018 Sep; 123(3):153-157. PubMed ID: 30251589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation affecting the proximal promoter of Endoglin as the origin of hereditary hemorrhagic telangiectasia type 1.
    Albiñana V; Zafra MP; Colau J; Zarrabeitia R; Recio-Poveda L; Olavarrieta L; Pérez-Pérez J; Botella LM
    BMC Med Genet; 2017 Feb; 18(1):20. PubMed ID: 28231770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1.
    Snellings DA; Gallione CJ; Clark DS; Vozoris NT; Faughnan ME; Marchuk DA
    Am J Hum Genet; 2019 Nov; 105(5):894-906. PubMed ID: 31630786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rendu-Osler disease: clinical and molecular update].
    Bailly S; Dupuis-Girod S; Plauchu H
    Med Sci (Paris); 2010 Oct; 26(10):855-60. PubMed ID: 20929677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular deficiency of Smad4 causes arteriovenous malformations: a mouse model of Hereditary Hemorrhagic Telangiectasia.
    Crist AM; Lee AR; Patel NR; Westhoff DE; Meadows SM
    Angiogenesis; 2018 May; 21(2):363-380. PubMed ID: 29460088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations.
    Pawlikowska L; Nelson J; Guo DE; McCulloch CE; Lawton MT; Young WL; Kim H; Faughnan ME;
    Am J Med Genet A; 2015 Jun; 167(6):1262-7. PubMed ID: 25847705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
    Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
    Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-β1 signaling in endothelial cells.
    Albiñana V; Sanz-Rodríguez F; Recio-Poveda L; Bernabéu C; Botella LM
    Mol Pharmacol; 2011 May; 79(5):833-43. PubMed ID: 21310938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Diagnosis of Hereditary Hemorrhagic Telangiectasia: Four Novel Pathogenic Variations in Turkish Patients.
    Baysal M; Demir S; Ümit EG; Gürkan H; Baş V; Karaman Gülsaran S; Demirci U; Kırkızlar HO; Demir AM
    Balkan Med J; 2019 Dec; 37(1):43-46. PubMed ID: 31594285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMAD4 Prevents Flow Induced Arteriovenous Malformations by Inhibiting Casein Kinase 2.
    Ola R; Künzel SH; Zhang F; Genet G; Chakraborty R; Pibouin-Fragner L; Martin K; Sessa W; Dubrac A; Eichmann A
    Circulation; 2018 Nov; 138(21):2379-2394. PubMed ID: 29976569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.